Ads
related to: dermatophagia medication reviews
Search results
Results from the WOW.Com Content Network
Dermatophagia (from Ancient Greek δέρμα — lit. skin and φαγεία lit. eating) or dermatodaxia (from δήξις, lit. biting) is a compulsion disorder of gnawing or biting one's own skin, most commonly at the fingers.
Reviews of treatment of excoriation disorder have shown that the following medications may be effective in reducing picking behavior: doxepin, clomipramine, naltrexone, pimozide, and olanzapine.
Cognitive behavioral therapy was cited as experimental evidence based therapy to treat trichotillomania and nail biting; a systematic review found best evidence for habit reversal training and decoupling. Another form of treatment that focuses on mindfulness, stimuli and rewards has proven effective in some people.
Other forms of pica include dermatophagia, and compulsion of eating one's own hair, which can form a hairball in the stomach. Left untreated, this can cause death due to excessive hair buildup. Self-cannibalism can be a form of self-harm and a symptom of a mental disorder.
Clinically dosage up to twice the recommended dose might be used due to relative resistance of some strains of dermatophytes. Tinea pedis is usually treated with topical medicines, like ketoconazole or terbinafine, and pills, or with medicines that contains miconazole, clotrimazole, or tolnaftate. [18]
Doxazosin, sold under the brand names Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate) and hypertension (high blood pressure). For high blood pressure, it is a less preferred option. It is taken by mouth.
Buccal administration may provide better bioavailability of some drugs and a more rapid onset of action compared to oral administration because the medication does not pass through the digestive system and thereby avoids first pass metabolism. [1] Drug forms for buccal administration include tablets and thin films .
Treatment with antiviral medication is recommended for all people with proven chronic hepatitis C who are not at high risk of death from other causes. People with the highest complication risk, which is based on the degree of liver scarring, should be treated first.
Skin and subcutaneous disorders are the most frequently reported, but these generally resolve after drug cessation. A 2012 review of etifoxine by the French National Pharmacovigilance Committee determined that etifoxine was safe and continued to provide a favorable alternative to benzodiazepine anxiolytics.
The medication is known to be an antioxidant, and oxidative stress has been hypothesized to be part of the process that kills neurons in people with ALS and in stroke victims. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.